International Clinical Trial: A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07813039) titled 'A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Vertex Pharmaceuticals Incorporated

Condition: Cystic Fibrosis

Intervention: Drug: VX-581

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 7, 2026

Target Sample Size: 16

To know more, visit https://clinicaltrials.gov/study/NCT07813039

Published by HT Digital Content Services with permission from Health D...